Content
Quantexa News
09/20
Chimerix (NASDAQ:CMRX) Shares Pass Below 200 Day Moving Average of $0.95
Chimerix, Inc. ( NASDAQ:CMRX – Get Free Report ) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.95 and traded as low as $0.86. Chimer...
Quantexa News
09/20
Chimerix (NASDAQ:CMRX) Shares Pass Below 200 Day Moving Average of $0.95
Chimerix, Inc. ( NASDAQ:CMRX – Get Free Report ) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.95 and traded as low as $0.86. Chimer...
Quantexa News
09/21
Chimerix (NASDAQ:CMRX) Stock Price Passes Below 200-Day Moving Average of $0.95
Chimerix, Inc. ( NASDAQ:CMRX – Get Free Report ) shares crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $0.95 and traded...
Quantexa News
09/21
Chimerix (NASDAQ:CMRX) Shares Cross Below Two Hundred Day Moving Average of $0.95
Chimerix, Inc. (NASDAQ:CMRX – Get Free Report)’s stock price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.95 and traded as low as...
Yahoo Finance News
09/22
Here's Why We're Watching Chimerix's (NASDAQ:CMRX) Cash Burn Situation
Here's Why We're Watching Chimerix's (NASDAQ:CMRX) Cash Burn Situation editorial-team@simplywallst.com (Simply Wall St) Sun, Sep 22, 2024, 6:22 AM 4 min read In This Article: CMRX We can readily under...
Quantexa News
10/05
Chimerix (NASDAQ:CMRX) Share Price Passes Above 200-Day Moving Average - What's Next?
Chimerix, Inc. (NASDAQ:CMRX - Get Free Report) shares passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.93 and traded as high as $0.93. Ch...
Quantexa News
10/05
Chimerix (NASDAQ:CMRX) Share Price Passes Above 200-Day Moving Average – What's Next?
Chimerix, Inc. ( NASDAQ:CMRX – Get Free Report ) shares passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.93 and traded as high as $0.93....
Quantexa News
10/06
Chimerix (NASDAQ:CMRX) Stock Passes Above 200 Day Moving Average – Here's What Happened
Shares of Chimerix, Inc. ( NASDAQ:CMRX – Get Free Report ) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.93 and traded as high as $0....
Quantexa News
10/06
Chimerix (NASDAQ:CMRX) Stock Passes Above Two Hundred Day Moving Average – What's Next?
Chimerix, Inc. ( NASDAQ:CMRX – Get Free Report )'s share price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.93 and traded as high as...
Quantexa News
10/16
Valeo Financial Advisors LLC Purchases 69,505 Shares of Chimerix, Inc. (NASDAQ:CMRX)
Valeo Financial Advisors LLC boosted its position in Chimerix, Inc. ( NASDAQ:CMRX – Free Report ) by 566.9% during the third quarter, HoldingsChannel reports. The fund owned 81,766 shares of the bioph...
Quantexa News
10/17
Chimerix, Inc. (NASDAQ:CMRX) Sees Large Decline in Short Interest
Chimerix, Inc. ( – ) saw a significant drop in short interest in the month of September. As of September 30th, there was short interest totalling 1,800,000 shares, a drop of 6.7% from the September 15...
Yahoo Finance News
10/18
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Chimerix, Inc. Fri, Oct 18, 2024, 4:31 PM 1 min read In This Article: CMRX +1.00% Chimerix, Inc. DURHAM, N.C., Oct. 18, 2024 (GLO...
Polygon News
10/18
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Chimerix, a biopharmaceutical company, announced that it granted stock options to a new employee as an inducement to employment. The options have a 10-year term and will vest over four years....
Quantexa News
10/25
Chimerix (NASDAQ:CMRX) Stock Price Crosses Below 200-Day Moving Average – Here's Why
Shares of Chimerix, Inc. ( NASDAQ:CMRX – Get Free Report ) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.91 and traded as low as $0....
Quantexa News
10/26
Chimerix (NASDAQ:CMRX) Shares Pass Below Two Hundred Day Moving Average – Should You Sell?
Chimerix, Inc. (NASDAQ:CMRX – Get Free Report) crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.91 and traded as low as $0.84. Chimeri...
Quantexa News
11/03
Chimerix (NASDAQ:CMRX) Share Price Passes Above 200-Day Moving Average – What’s Next?
Shares of Chimerix, Inc. (NASDAQ:CMRX – Get Free Report) passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.91 and traded a...
Quantexa News
11/03
Chimerix (NASDAQ:CMRX) Share Price Passes Above 200-Day Moving Average – What's Next?
Chimerix, Inc. ( NASDAQ:CMRX – Get Free Report ) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.91 and traded as high as $1.00. Chimeri...
Quantexa News
11/04
Assenagon Asset Management S.A. Sells 83,793 Shares of Chimerix, Inc. (NASDAQ:CMRX)
Assenagon Asset Management S.A. lowered its stake in shares of Chimerix, Inc. ( NASDAQ:CMRX – Free Report ) by 20.7% in the 3rd quarter, according to the company in its most recent disclosure with the...
Yahoo Finance News
11/06
Chimerix Inc (CMRX) Q3 2024: Everything You Need to Know Ahead of Earnings
Chimerix Inc (CMRX) Q3 2024: Everything You Need to Know Ahead of Earnings GuruFocus News Wed, Nov 6, 2024, 7:50 AM 2 min read In This Article: CMRX -1.50% Chimerix Inc ( NASDAQ:CMRX ) is set to relea...
Quantexa News
11/06
Chimerix Inc (CMRX) Q3 2024: Everything You Need to Know Ahead of Earnings
Chimerix Inc (NASDAQ:CMRX) is set to release its Q3 2024 earnings on Nov 7, 2024. The consensus estimate for Q3 2024 revenue is $0.08 million, and the earnings are expected to come in at -$0.24 per sh...
Yahoo Finance Community
11/06
Comment
In regards to tomorrow's cc - It is possible that management will have an update on the status of the onc201 australian early approval. It is my understanding that onc201 could be approved late next year if australian officials give it the green light. Not sure if any updates on onc206 will be available. It may be too early in the year. EBS did have some sales of tembexa in the 3rd qtr but not sure if that facilitated a monetary payment to CMRX. CMRX will still have a large cash pile that can fund expenses into 2026. This is definitely a very strong asset especially considering CMRX also has zero debt and a low share count....
Votes:
3
0
Yahoo Finance News
11/08
Chimerix Inc (CMRX) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid Financial ...
Chimerix Inc (CMRX) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid Financial ... GuruFocus News Thu, Nov 7, 2024, 11:12 PM 4 min read In This Article: CMRX -1.50% Net Loss: $22.9 millio...
Yahoo Finance Community
11/08
Comment
Yesterday's cc was extremely brief with only 1 analyst who asked a question. I think it barely lasted 14 minutes. Kind of embarrassing. Of course, no onc201 enrollment numbers were given but management still expects interim result in q3 2025. No new info regarding onc206 - still enrolling dose escalation study but it appears that they are now in the last cohort. Good to hear that no dose toxicity has been reached in the current dosages. One good nugget of info is that CMRX will be receiving a little over 2 million dollars from the EBS tembexa agreement. Apparently, the 2 million dollar dollars was not reported in the 3rd quarter because the payment was yet to be received. One other good nugget is the EBS has started a trial of Tembexa for monkeypox. CMRX receives 15% royalties on gross profit from all non-US sales. EBS actually investing their cash …...
Votes:
6
0
Quantexa News
11/09
Chimerix, Inc. (NASDAQ:CMRX) Q3 2024 Earnings Call Transcript
Chimerix, Inc. (NASDAQ: CMRX ) Q3 2024 Earnings Call Transcript November 7, 2024 Chimerix, Inc. misses on earnings expectations. Reported EPS is $-0.26 EPS, expectations were $-0.24. Operator: Good...
Yahoo Finance News
11/11
Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting
Chimerix Announces Updated Phase 2 Response Assessment of Dordaviprone in Recurrent H3 K27M Glioma at the 2024 SNO Meeting Chimerix, Inc. Mon, Nov 11, 2024, 5:00 AM 4 min read In This Article: CMRX -1...
Quantexa News
11/11
No matter how cynical the overall market is, Chimerix Inc (CMRX) performance over the last week is recorded 0.00%
On Friday, Chimerix Inc (NASDAQ: CMRX) was 5.87% up from the session before settling in for the closing price of $0.94. A 52-week range for CMRX has been $0.75 – $1.30. Here's Your FREE Report on the...
Yahoo Finance Community
11/13
Comment
Tom, your comments are just superb. Thanks for all the insights and it seem that you have a lot of experience. One question: what would you think is the valuation of Crmx at this point, if a company would like to aquire it? Does this even make sense to buy it with its status quo by now? Cheers...
Votes:
2
0
Quantexa News
11/17
Short Interest in Chimerix, Inc. (NASDAQ:CMRX) Decreases By 12.6%
Chimerix, Inc. ( NASDAQ:CMRX – Get Free Report ) was the recipient of a large decrease in short interest in the month of October. As of October 31st, there was short interest totalling 1,520,000 share...
Quantexa News
11/18
Chimerix, Inc. (NASDAQ:CMRX) Sees Large Decrease in Short Interest
Chimerix, Inc. ( NASDAQ:CMRX – Get Free Report ) saw a large decrease in short interest in October. As of October 31st, there was short interest totalling 1,520,000 shares, a decrease of 12.6% from th...
Quantexa News
11/18
Chimerix, Inc. (NASDAQ:CMRX) Sees Large Decrease in Short Interest
Chimerix, Inc. ( NASDAQ:CMRX – Get Free Report ) was the target of a large decline in short interest in October. As of October 31st, there was short interest totalling 1,520,000 shares, a decline of 1...
Yahoo Finance Community
11/22
Comment
Prior year end (more specifically Christmas eve), CMRX will need to either have its share price above $1.00 for 10 trading days or take other actions. One option would be to switch to the Nasdaq Capital Market exchange whereby they could avoid the reverse split for another 180 days. CMRX should also complete its Australian onc201 application and also complete onc206 trial....
Votes:
1
0
Quantexa News
11/28
Chimerix, Inc. (NASDAQ:CMRX) Sees Large Decrease in Short Interest
Chimerix, Inc. (NASDAQ:CMRX – Get Free Report) was the target of a large drop in short interest in November. As of November 15th, there was short interest totalling 710,300 shares, a drop of 53.3% fro...
Yahoo Finance Community
12/03
Comment
As of 11/15/24, the short interest for CMRX has dipped to a little over 700,000 shares. This is a very significant reduction and it could portend to a price uptick in the upcoming weeks. As posted earlier, the onc 201 australian early approval application should be submitted by year end and we should also have a press release regarding the next steps for onc 206. Onc 201 enrollment needs to stay on track as management has already moved the goalposts 2x (initially it was reported that preliminary data would be out in "early" 2025, then mid 2025, and now it is "expected" in q3.)...
Votes:
3
0
Yahoo Finance News
12/06
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Chimerix, Inc. Fri, Dec 6, 2024, 4:01 PM 1 min read In This Article: CMRX -3.26% Chimerix, Inc. DURHAM, N.C., Dec. 06, 2024 (GLO...
Yahoo Finance Community
12/09
Comment
Notable increase in volume today. Would be nice if this results in share price appreciation during the next few trading days. As we all know, the nasdaq $1.00 price listing requirement is an issue that needs to be resolved by Christmas Eve and it looks like CMRX might have to switch to the nasdaq capital market in order to maintain compliancy. This would be better than the R/S. I still think that CMRX will finalize its Australian onc201 application and also provide some update on onc206 prior to year end. Management will then be able to tout these achievements when they grant themselves more options and bonuses early next year. Unfortunately, this is how the game is played....
Votes:
3
1
Yahoo Finance News
12/09
Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End
Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End Chimerix, Inc. Mon, Dec 9, 2024, 11:01 PM 5 min read In T...
Quantexa News
12/09
Chimerix Inc (CMRX) Shares Up Despite Recent Market Volatility
Chimerix Inc (NASDAQ: CMRX)'s stock price has increased by 3.97 compared to its previous closing price of 0.83. However, the company has seen a -2.79% decrease in its stock price over the last five tr...
Yahoo Finance Community
12/10
Comment
Huge overhead supply and year of pain trade: too many people with far too many shares hve been sitting on losing position, and would rather ell quickly and move away from the stock no matter thefuture Therefore, PPS is likely go much lower relative the pre-market. Add a huge float, and I think the stock may well drop to 1.50 - 1.60 range....
Votes:
2
0
Yahoo Finance Community
12/10
Comment
Wall Street valuing CMRX at 50% of cash yesterday.Up 170% right now to trade at .70 cents above cash.Path for accelerated approval of brain cancer condition impacting 2k people annually in US and a lot more globally. Company has a pipeline of multiple drugs.Am I concerned about a selloff against move today? C'mon man!!...
Votes:
1
0
Yahoo Finance Community
12/10
Comment
Journey into the captivating realm of finance, a cosmos filled with promise and hidden obstacles. With a trusted advisor by your side, traverse the wondrous landscape with wisdom and insight, discovering hidden riches and charting a course towards a future overflowing with prosperity and enduring financial harmony....
Votes:
1
0
Yahoo Finance News
12/10
Chimerix Shares Soar Following Plans to Seek Accelerated Approval for Dordaviprone in Rare Brain Tumor
PREMIUM Chimerix Shares Soar Following Plans to Seek Accelerated Approval for Dordaviprone in Rare Brain Tumor MT Newswires Tue, Dec 10, 2024, 10:33 AM 1 min read In This Article: CMRX +219.08% Chimer...
Yahoo Finance Community
12/10
Comment
Those of us who've been cost-averaging down and accumulating CMRX for the past couple of years are all smiles today. And those who doubted/criticized management have egg on their faces. That said, there is a shelf registration that we might expect to come into play in coming months to fund ONC206, but I think the price needs to get closer to $5-6 before issuance....
Votes:
2
0
Yahoo Finance News
12/10
Chimerix Soars 220% on FDA Filing Plans for Lifesaving Brain Cancer Therapy
Chimerix Soars 220% on FDA Filing Plans for Lifesaving Brain Cancer Therapy Muslim Farooque Tue, Dec 10, 2024, 10:51 AM 1 min read In This Article: CMRX +219.08% Tuesday after the biotech company reve...
Quantexa News
12/10
Chimerix Stock Draws Heavy Retail Chatter After Landing Price-Target Hike On FDA Submission Plan For Cancer Drug
Following the news, JonesResearch raised its price target on Chimerix to $7 from $5 while maintaining a ‘Buy’ rating. Shares of Chimerix Inc. (CMRX) more than tripled on Tuesday afternoon, reaching l...
Quantexa News
12/12
Chimerix Inc (NASDAQ: CMRX): Moving Toward A Higher Share Price
Chimerix Inc (NASDAQ:CMRX) shares, rose in value on Wednesday, December 11, with the stock price up by 7.97% to the previous day's close as strong demand from buyers drove the stock to $2.98. Activel...
Quantexa News
12/13
Chimerix Inc (CMRX) volume hits 6.02 million: A New Opening for Investors
Chimerix Inc (NASDAQ: CMRX) open the trading on Thursday, with a bit cautious approach as it glided -1.34% to $2.94, before settling in for the price of $2.98 at the close. Taking a more long-term app...
Quantexa News
12/14
Wedbush Comments on Chimerix's Q2 Earnings (NASDAQ:CMRX)
Chimerix, Inc. ( NASDAQ:CMRX – Free Report ) – Stock analysts at Wedbush lowered their Q2 2025 earnings estimates for shares of Chimerix in a report issued on Monday, December 9th. Wedbush analyst D....
Quantexa News
12/15
HC Wainwright Has Positive Estimate for Chimerix Q4 Earnings
Chimerix, Inc. ( NASDAQ:CMRX – Free Report ) – Investment analysts at HC Wainwright upped their Q4 2024 earnings per share estimates for shares of Chimerix in a research report issued to clients and i...
Quantexa News
12/15
Wedbush Has Pessimistic Outlook of Chimerix Q4 Earnings
Chimerix, Inc. ( NASDAQ:CMRX – Free Report ) – Research analysts at Wedbush decreased their Q4 2025 earnings per share (EPS) estimates for Chimerix in a research report issued on Tuesday, December 10t...
Quantexa News
12/16
Chimerix Inc (CMRX) Shares Have Inclined 206.49% Year To Date
Chimerix Inc (NASDAQ:CMRX) has a beta value of 0.90 and has seen 2.61 million shares traded in the last trading session. The company, currently valued at $266.21M, closed the last trade at $2.95 per s...
Quantexa News
12/16
Chimerix, Inc. (NASDAQ:CMRX) Sees Significant Drop in Short Interest
Chimerix, Inc. ( NASDAQ:CMRX – Get Free Report ) saw a significant decrease in short interest during the month of November. As of November 30th, there was short interest totalling 647,700 shares, a de...
Yahoo Finance Community
12/17
Comment
It’s not surprising that we’re stabilizing after tripling last week. But for me, there’s still a lot of potential good news coming: EOY - NDA filing for ONC201 accelerated approval - Removal from NASDAQ’s naughty list - completion of ONC206 phase 1 trial Q1 - Phase 1 Results and plans for ONC206 phase 2 trials Q2 - ONC201 potential approval...
Votes:
4
0
Quantexa News
12/17
Chimerix, Inc. (NASDAQ:CMRX) Sees Significant Decline in Short Interest
Chimerix, Inc. (NASDAQ:CMRX – Get Free Report) was the recipient of a large decrease in short interest during the month of November. As of November 30th, there was short interest totalling 647,700 sha...
Quantexa News
12/17
Chimerix, Inc. (NASDAQ:CMRX) Short Interest Down 8.8% in November
Chimerix, Inc. (NASDAQ:CMRX – Get Free Report) was the target of a large decrease in short interest in the month of November. As of November 30th, there was short interest totalling 647,700 shares, a...
Quantexa News
12/17
Chimerix, Inc. (NASDAQ:CMRX) Sees Significant Decline in Short Interest
Chimerix, Inc. ( NASDAQ:CMRX – Get Free Report ) was the target of a large decline in short interest in the month of November. As of November 30th, there was short interest totalling 647,700 shares, a...
Quantexa News
12/18
Investors finally get a glimpse of Chimerix Inc (CMRX) volume hitting the figure of 2.11 million.
Chimerix Inc (NASDAQ: CMRX) kicked off on Tuesday, down -3.44% from the previous trading day, before settling in for the closing price of $2.91. Over the past 52 weeks, CMRX has traded in a range of $...
Quantexa News
12/24
Could Chimerix Inc (NASDAQ: CMRX) Be The Biggest Winner?
In the last trading session, 1.16 million Chimerix Inc (NASDAQ:CMRX) shares changed hands as the company's beta touched 0.60. With the company's per share price at $3.02 changed hands at $0.03 or 1.00...
Quantexa News
12/24
Chimerix Inc (CMRX) Stock: A Look at the Analyst Recommendations
CMRX has 36-month beta value of 0.70. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.” The public float for CMRX is 80.14...
Quantexa News
12/27
Chimerix, Inc. (NASDAQ:CMRX) Short Interest Up 431.1% in December
Chimerix, Inc. ( NASDAQ:CMRX – Get Free Report ) was the target of a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 3,440,000 sh...
Quantexa News
12/27
Chimerix, Inc. (NASDAQ:CMRX) Short Interest Up 431.1% in December
NASDAQ:CMRX – Get Free Report ) saw a large increase in short interest in December. As of December 15th, there was short interest totalling 3,440,000 shares, an increase of 431.1% from the November 30...
Quantexa News
12/28
Chimerix, Inc. (NASDAQ:CMRX) Sees Significant Growth in Short Interest
Chimerix, Inc. ( NASDAQ:CMRX – Get Free Report ) was the target of a large increase in short interest during the month of December. As of December 15th, there was short interest totalling 3,440,000 sh...
Yahoo Finance News
12/30
Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma
Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Chimerix, Inc. Mon, Dec 30, 2024, 7:00 AM 4 min read I...
Yahoo Finance News
12/30
Chimerix Seeks Accelerated FDA Approval for Experimental Tumor Drug
PREMIUM Chimerix Seeks Accelerated FDA Approval for Experimental Tumor Drug MT Newswires Mon, Dec 30, 2024, 7:26 AM 1 min read In This Article: CMRX -0.58% Chimerix (CMRX) said Monday it has submitted...
Quantexa News
12/30
Chimerix (NASDAQ: CMRX) Enters Amended Loan Agreement with Silicon Valley Bank
Chimerix Inc. announced on December 23, 2024, that the company has entered into an Amended and Restated Loan and Security Agreement with Silicon Valley Bank, a division of First-Citizens Bank & Trust...
Quantexa News
12/30
Chimerix, Inc. Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma
Chimerix, Inc. has submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) seeking accelerated approval for dordaviprone as a treatment for patients with recurrent H3 K...
Quantexa News
01/01
Chimerix, Inc. Enters into Amended and Restated Loan and Security Agreement
December 30, 2024 at 07:21 am EST On December 23, 2024 (the Effective Date"), Chimerix, Inc. (the Company") entered into an Amended and Restated Loan and Security Agreement (the Loan Agreement"), by...
Quantexa News
01/02
Chimerix Inc (NASDAQ: CMRX) Inclined 282.30% Over The Last Month – Are There Ways To Succeed From This Incline?
During the recent session, Chimerix Inc (NASDAQ:CMRX)'s traded shares were 0.42 million, with the beta value of the company hitting 0.36. At the last check today, the stock's price was $3.40, reflecti...
Yahoo Finance Community
01/04
Comment
It seems like the most likely path for ONC201 now that the new drug application has been filed is: In 60 days (end of February) the FDA will complete their filing review and tell Chimerix whether they accept the NDA and if they’ll give the priority review. Assuming they accept the NDA and agree to priority review, we should know the outcome of accelerated approval in six months....
Quantexa News
01/07
Chimerix (NASDAQ:CMRX) Share Price Crosses Above 50 Day Moving Average - Should You Sell?
Chimerix, Inc. (NASDAQ:CMRX - Get Free Report)'s stock price crossed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $1.82 and traded as high as $3....
Quantexa News
01/07
Chimerix (NASDAQ:CMRX) Share Price Crosses Above 50 Day Moving Average – Should You Sell?
Chimerix, Inc. (NASDAQ:CMRX – Get Free Report)’s stock price crossed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $1.82 and traded as high as $3....
Quantexa News
01/07
Chimerix (NASDAQ:CMRX) Stock Price Crosses Above Fifty Day Moving Average – Time to Sell?
Shares of Chimerix, Inc. ( NASDAQ:CMRX – Get Free Report ) crossed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $1.82 and traded as high as $3.80...
Quantexa News
01/11
Geode Capital Management LLC Trims Holdings in Chimerix, Inc. (NASDAQ:CMRX)
Geode Capital Management LLC reduced its holdings in shares of Chimerix, Inc. (NASDAQ:CMRX – Free Report) by 4.5% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund...
Quantexa News
01/11
Geode Capital Management LLC Decreases Holdings in Chimerix, Inc. (NASDAQ:CMRX)
Geode Capital Management LLC reduced its position in Chimerix, Inc. (NASDAQ:CMRX – Free Report) by 4.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commiss...
Quantexa News
01/14
Chimerix, Inc. (NASDAQ:CMRX) Sees Large Decline in Short Interest
Chimerix, Inc. (NASDAQ:CMRX - Get Free Report) saw a large decline in short interest during the month of December. As of December 31st, there was short interest totalling 1,810,000 shares, a decline o...
Quantexa News
01/15
Marquette Asset Management LLC Reduces Stake in Chimerix, Inc. (NASDAQ:CMRX)
Marquette Asset Management LLC lowered its position in Chimerix, Inc. (NASDAQ:CMRX – Free Report) by 6.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange C...
Yahoo Finance Community
01/19
Comment
There's a big chance Chimerix will be acquired within this year. It might happen even before ONC201 is approved by the FDA. Although ONC201 is for patients with newly diagnosed H3 K27M-mutant diffuse glioma following radiotherapy treatment and it is not a cure but only to extend life. But the main point is there is no OTHER DRUG available to treat the disease. Market size for ONC201 is approximately $750M according to management and they have ONC206 in phase 1 trial and ONC212 in preclinical study.If the J.P. Morgan Healthcare Conference is any prediction 2025 will be a HOT year for M&A. CMRX current market cap is only $310 mil, it is peanut for any mid cap and sesame seed for any big cap biotech to acquire....
Votes:
2
1
Quantexa News
01/23
Evaluating the Impact of 4.20 Increase on Chimerix Inc's (CMRX) Stock
The stock of Chimerix Inc (CMRX) has seen a 13.51% increase in the past week, with a 38.20% gain in the past month, and a 347.59% flourish in the past quarter. The volatility ratio for the week is 9.9...
Quantexa News
01/27
Chimerix Inc (CMRX) recent activity suggests a positive outlook with the last week's performance of 8.20%
Chimerix Inc (NASDAQ: CMRX) on Friday, soared 3.39% from the previous trading day, before settling in for the closing price of $3.83. Within the past 52 weeks, CMRX's price has moved between $0.75 and...
Quantexa News
01/30
Chimerix (NASDAQ:CMRX) Share Price Passes Above 200 Day Moving Average – Should You Sell?
Chimerix, Inc. (NASDAQ:CMRX – Get Free Report)’s stock price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.55 and traded as high as...
Quantexa News
01/30
Chimerix (NASDAQ:CMRX) Share Price Passes Above Two Hundred Day Moving Average – Here’s Why
Chimerix, Inc. (NASDAQ:CMRX – Get Free Report) crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.55 and traded as high as $4.14. Chime...
Quantexa News
01/30
Chimerix (NASDAQ:CMRX) Share Price Passes Above Two Hundred Day Moving Average - Here's Why
Chimerix, Inc. (NASDAQ:CMRX - Get Free Report) crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.55 and traded as high as $4.14. Chime...
Quantexa News
02/01
Insider Selling: Chimerix, Inc. (NASDAQ:CMRX) VP Sells 2,800 Shares of Stock
Chimerix, Inc. (NASDAQ:CMRX – Get Free Report) VP David Jakeman sold 2,800 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average pri...
Quantexa News
02/03
Chimerix, Inc. (NASDAQ:CMRX) VP Sells $11,480.00 in Stock
Chimerix, Inc. ( NASDAQ:CMRX – Get Free Report ) VP David Jakeman sold 2,800 shares of Chimerix stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $4.10,...
Quantexa News
02/03
David Jakeman Sells 2,800 Shares of Chimerix, Inc. (NASDAQ:CMRX) Stock
Chimerix, Inc. ( NASDAQ:CMRX – Get Free Report ) VP David Jakeman sold 2,800 shares of the business's stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $4....
Quantexa News
02/04
Chimerix Inc (CMRX) posted a -5.71% change over the last five days signaling a new trend
A new trading day began on Monday, with Chimerix Inc (NASDAQ: CMRX) stock price down -3.55% from the previous day of trading, before settling in for the closing price of $3.94. CMRX's price has ranged...
Yahoo Finance Community
02/06
Comment
I don't understand the Wainwright analyst's price estimate of $11. If ONC201/dordaviprone is accepted for priority review later this month, and if it's approved after 6 more months, the stock is worth $20 or more based on commonly used price-to-sales metrics. If not accepted for priority review, it could still be approved within 1-2 years following conclusion of the current P3 trial, and again, the price potential is $20 or more. If approval is not granted, the stock is worth less than $1 again. Maybe they're saying it's a 50-50 chance for approval and averaging the high and low potential prices? Maybe they're factoring in a potential sale price prior to FDA approval? But the CMRX board would be nuts to take $11 now....
Votes:
1
0
Quantexa News
02/10
Chimerix, Inc. (NASDAQ:CMRX) Position Increased by Stoneridge Investment Partners LLC
Stoneridge Investment Partners LLC boosted its stake in Chimerix, Inc. (NASDAQ:CMRX – Free Report) by 22.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and...
Quantexa News
02/12
The 198.54% Simple Moving Average of Chimerix Inc’s (CMRX) Stock in the Past 200 Days
The stock of Chimerix Inc (CMRX) has seen a 10.94% increase in the past week, with a 34.15% gain in the past month, and a 366.26% flourish in the past quarter. The volatility ratio for the week is 6.8...
Quantexa News
02/12
Chimerix Inc (NASDAQ: CMRX)'s Stock Market Position Could Improve In The Coming Months
In the last trading session, 2.09 million shares of the Chimerix Inc (NASDAQ:CMRX) were traded, and its beta was 0.38. Most recently the company's share price was $4.36, and it changed around $0.3 or...
Quantexa News
02/15
Chimerix, Inc. (NASDAQ:CMRX) CFO Michelle Laspaluto Sells 2,260 Shares of Stock
Chimerix, Inc. ( NASDAQ:CMRX – Get Free Report ) CFO Michelle Laspaluto sold 2,260 shares of the business's stock in a transaction on Thursday, February 13th. The shares were sold at an average price...
Quantexa News
02/15
Insider Selling: Chimerix, Inc. (NASDAQ:CMRX) Insider Sells 3,065 Shares of Stock
Chimerix, Inc. (NASDAQ:CMRX – Get Free Report) insider Allen S. Melemed sold 3,065 shares of the company’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of...
Quantexa News
02/15
Chimerix, Inc. (NASDAQ:CMRX) Insider Allen S. Melemed Sells 3,065 Shares of Stock
Chimerix, Inc. (NASDAQ:CMRX – Get Free Report) insider Allen S. Melemed sold 3,065 shares of Chimerix stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average...
Quantexa News
02/15
Chimerix, Inc. (NASDAQ:CMRX) CEO Michael T. Andriole Sells 7,370 Shares
Chimerix, Inc. (NASDAQ:CMRX - Get Free Report) CEO Michael T. Andriole sold 7,370 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price...
Quantexa News
02/15
Chimerix, Inc. (NASDAQ:CMRX) Insider Sells $13,792.50 in Stock
Chimerix, Inc. (NASDAQ:CMRX - Get Free Report) insider Allen S. Melemed sold 3,065 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $4.50, for...
Quantexa News
02/15
Insider Selling: Chimerix, Inc. (NASDAQ:CMRX) CFO Sells 2,260 Shares of Stock
Chimerix, Inc. (NASDAQ:CMRX - Get Free Report) CFO Michelle Laspaluto sold 2,260 shares of the firm's stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of...
Quantexa News
02/16
Insider Selling: Chimerix, Inc. (NASDAQ:CMRX) CEO Sells 7,370 Shares of Stock
Chimerix, Inc. (NASDAQ:CMRX – Get Free Report) CEO Michael T. Andriole sold 7,370 shares of the company’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of...
Quantexa News
02/16
Palumbo Wealth Management LLC Invests $221,000 in Chimerix, Inc. (NASDAQ:CMRX)
Palumbo Wealth Management LLC purchased a new stake in shares of Chimerix, Inc. ( NASDAQ:CMRX – Free Report ) in the 4th quarter, HoldingsChannel reports. The institutional investor purchased 63,400 s...
Quantexa News
02/16
Chimerix, Inc. (NASDAQ:CMRX) Insider Sells $13,792.50 in Stock
Chimerix, Inc. ( NASDAQ:CMRX – Get Free Report ) insider Allen S. Melemed sold 3,065 shares of the business's stock in a transaction that occurred on Thursday, February 13th. The shares were sold at a...
Quantexa News
02/16
Michelle Laspaluto Sells 2,260 Shares of Chimerix, Inc. (NASDAQ:CMRX) Stock
Chimerix, Inc. ( NASDAQ:CMRX – Get Free Report ) CFO Michelle Laspaluto sold 2,260 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average pri...
Quantexa News
02/17
Insider Selling: Chimerix, Inc. (NASDAQ:CMRX) CEO Sells 7,370 Shares of Stock
Chimerix, Inc. ( NASDAQ:CMRX – Get Free Report ) CEO Michael T. Andriole sold 7,370 shares of the company's stock in a transaction dated Thursday, February 13th. The stock was sold at an average price...
Quantexa News
02/17
Insider Selling: Chimerix, Inc. (NASDAQ:CMRX) CEO Sells $33,312.40 in Stock
Chimerix, Inc. ( NASDAQ:CMRX – Get Free Report ) CEO Michael T. Andriole sold 7,370 shares of the business's stock in a transaction on Thursday, February 13th. The stock was sold at an average price o...
Quantexa News
02/17
Insider Selling: Chimerix, Inc. (NASDAQ:CMRX) CFO Sells $10,192.60 in Stock
Chimerix, Inc. (NASDAQ:CMRX – Get Free Report) CFO Michelle Laspaluto sold 2,260 shares of the firm’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $4...
Quantexa News
02/17
Michelle Laspaluto Sells 2,260 Shares of Chimerix, Inc. (NASDAQ:CMRX) Stock
Chimerix, Inc. ( NASDAQ:CMRX – Get Free Report ) CFO Michelle Laspaluto sold 2,260 shares of Chimerix stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average...
Quantexa News
02/17
Chimerix, Inc. (NASDAQ:CMRX) Insider Sells $13,792.50 in Stock
Chimerix, Inc. ( NASDAQ:CMRX – Get Free Report ) insider Allen S. Melemed sold 3,065 shares of the business's stock in a transaction dated Thursday, February 13th. The shares were sold at an average p...
Quantexa News
02/17
Chimerix, Inc. (NASDAQ:CMRX) Insider Sells $13,792.50 in Stock
Chimerix, Inc. ( – ) insider Allen S. Melemed sold 3,065 shares of the company's stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $4.50, for...
Yahoo Finance News
02/18
Chimerix Announces FDA Acceptance and Priority Review of New Drug Application for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma
Chimerix Announces FDA Acceptance and Priority Review of New Drug Application for Dordaviprone as Treatment for Recurrent H3 K27M-Mutant Diffuse Glioma Chimerix, Inc. Tue, Feb 18, 2025, 6:00 AM 3 min...
Quantexa News
02/18
Wedbush Adjusts Price Target on Chimerix to $7 From $6, Keeps Outperform Rating
Chimerix, Inc. is a biotechnology company. The Company is focused on developing medicines that address unmet medical needs. The Company's product Imipridones is a cancer therapy that provides ONC201,...
Yahoo Finance News
02/18
Chimerix Says FDA Grants Priority Review for New Drug Application of Cancer Treatment Dordaviprone; Shares Rise
PREMIUM Chimerix Says FDA Grants Priority Review for New Drug Application of Cancer Treatment Dordaviprone; Shares Rise MT Newswires Tue, Feb 18, 2025, 10:53 AM In This Article: CMRX +10.27% Chimerix...
Quantexa News
02/18
Chimerix Says FDA Grants Priority Review for New Drug Application of Cancer Treatment Dordaviprone; Shares Rise
Chimerix, Inc. is a biotechnology company. The Company is focused on developing medicines that address unmet medical needs. The Company's product Imipridones is a cancer therapy that provides ONC201,...
Yahoo Finance News
02/18
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Chimerix, Inc. Tue, Feb 18, 2025, 11:01 PM 1 min read In This Article: CMRX +10.27% Chimerix, Inc. DURHAM, N.C., Feb. 18, 2025 (...
Quantexa News
02/19
Why Chimerix, Inc.'s (CMRX) Stock Is Up 10.27%
Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Chimerix, Inc. before investing. In this article, we go over a few key elements...
Quantexa News
02/20
Wedbush Has Optimistic Outlook of Chimerix FY2025 Earnings
Chimerix, Inc. ( NASDAQ:CMRX – Free Report ) – Analysts at Wedbush upped their FY2025 earnings per share estimates for shares of Chimerix in a research report issued on Tuesday, February 18th. Wedbush...
Quantexa News
02/20
Now Is The Time To Build A Position In Chimerix Inc (NASDAQ:CMRX)
In last trading session, Chimerix Inc (NASDAQ:CMRX) saw 4.45 million shares changing hands with its beta currently measuring 0.38. Company's recent per share price level of $5.08 trading at $0.25 or 5...
Quantexa News
02/21
Wedbush Has Positive Estimate for Chimerix FY2028 Earnings
Chimerix, Inc. ( NASDAQ:CMRX – Free Report ) – Investment analysts at Wedbush upped their FY2028 earnings per share (EPS) estimates for shares of Chimerix in a report issued on Tuesday, February 18th....
Yahoo Finance News
02/21
Exploring Three High Growth Tech Stocks in the United States
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Exploring Three High Growth Tech Stocks in the United States editorial-team@simplywallst.com (Simply Wall St) Fri, F...
Quantexa News
02/22
Wedbush Has Bullish Forecast for Chimerix FY2025 Earnings
Chimerix, Inc. ( NASDAQ:CMRX – Free Report ) – Stock analysts at Wedbush raised their FY2025 earnings per share (EPS) estimates for shares of Chimerix in a note issued to investors on Tuesday, Februar...
Quantexa News
02/22
Vontobel Holding Ltd. Sells 30,000 Shares of Chimerix, Inc. (NASDAQ:CMRX)
Vontobel Holding Ltd. cut its position in Chimerix, Inc. ( NASDAQ:CMRX – Free Report ) by 42.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities...
Quantexa News
02/22
Vontobel Holding Ltd. Sells 30,000 Shares of Chimerix, Inc. (NASDAQ:CMRX)
Vontobel Holding Ltd. cut its position in shares of Chimerix, Inc. (NASDAQ:CMRX – Free Report) by 42.9% during the 4th quarter, Holdings Channel.com reports. The firm owned 40,000 shares of the biopha...
Quantexa News
03/03
Future Outlook And Stock Price Performance For Chimerix Inc (NASDAQ: CMRX)
In today's recent session, 0.66 million shares of the Chimerix Inc (NASDAQ:CMRX) have been traded, and its beta is 0.32. Most recently the company's share price was $5.14, and it changed around -$0.11...
Quantexa News
03/04
Chimerix Inc (NASDAQ: CMRX) Analysts Expect It Could Climb 46.38% From Current Levels.
The trading price of Chimerix Inc (NASDAQ:CMRX) closed lower on Monday, March 03, and closing at $5.04, -4.00% lower than its previous close. In examining the 52-week price action we see that the sto...
Polygon News
03/04
Dopamine Receptor Antagonists Clinical Trial Pipeline Analysis: 10+ Key Companies Shaping the Future of Dopamine Receptor Antagonists Therapeutics | DelveInsight
The dopamine receptor antagonist market is poised for significant growth, driven by the increasing prevalence of psychiatric disorders and the rising demand for more effective treatments with fewer si...
Yahoo Finance News
03/05
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio PR Newswire Wed, Mar 5, 2025, 7:00...
Quantexa News
03/05
Form SC14D9C - Written communication relating to third party tender offer
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Chime...
Yahoo Finance News
03/05
Jazz Pharmaceuticals to Acquire Chimerix in $935 Million Deal
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now PREMIUM Jazz Pharmaceuticals to Acquire Chimerix in $935 Million Deal MT Newswires Wed, Mar 5, 2025, 4:26 AM In This...
Quantexa News
03/05
CHIMERIX, INC. Jazz Pharmaceuticals to Acquire Chimerix in $935 Million Deal
Chimerix, Inc. is a biotechnology company. The Company is focused on developing medicines that address unmet medical needs. The Company's product Imipridones is a cancer therapy that provides ONC201,...
Quantexa News
03/05
CMRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Chimerix, Inc. Is Fair to Shareholders
March 05, 2025 at 07:54 AM EST Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Chimerix, Inc. (NASDAQ: CMRX) to Jazz Pharmaceuticals plc for $8.55 per share in cas...
Quantexa News
03/05
CMRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Chimerix, Inc. Is Fair to Shareholders
By: Halper Sadeh LLC via Business Wire Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Chimerix, Inc. (NASDAQ: CMRX) to Jazz Pharmaceuticals plc for $8.55 per shar...
Quantexa News
03/05
CMRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Chimerix, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Chimerix, Inc. (NASDAQ: CMRX) to Jazz Pharmaceuticals plc for $8.55 per share in cash is fair to Chimerix shareholde...
Quantexa News
03/05
CHIMERIX, INC. CMRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Chimerix, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Chimerix, Inc. (NASDAQ: CMRX) to Jazz Pharmaceuticals plc for $8.55 per share in cash is fair to Chimerix shareholde...
Quantexa News
03/05
CMRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Chimerix, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Chimerix, Inc. (NASDAQ: CMRX) to Jazz Pharmaceuticals plc for $8.55 per share in cash is fair to Chimerix shareholde...
Quantexa News
03/05
CMRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Chimerix, Inc. Is Fair to Shareholders
Decatur, IN Today Windy with occasional light rain. Thunder possible. Morning high of 55F with temps falling to near 40. Winds SSW at 20 to 30 mph. Chance of rain 70%.. Tonight Windy with snow s...
Quantexa News
03/05
CMRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Chimerix, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Mar 5, 2025-- Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Chimerix, Inc. (NASDAQ: CMRX) to Jazz Pharmaceuticals plc for $8.55 per sh...
Quantexa News
03/05
CMRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Chi
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Chimerix, Inc. (NASDAQ: CMRX) to Jazz Pharmaceuticals plc for $8.55 per share in cash is fair to Chimerix shareholde...
Quantexa News
03/05
CMRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Chimerix, Inc. Is Fair to Shareholders
NEW YORK --(BUSINESS WIRE) Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Chimerix, Inc. (NASDAQ: CMRX) to Jazz Pharmaceuticals plc for $8.55 per share in cash is...
Quantexa News
03/05
CMRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Chimerix, Inc. Is Fair to Shareholders
March 05, 2025 at 07:54 AM EST Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Chimerix, Inc. (NASDAQ: CMRX) to Jazz Pharmaceuticals plc for $8.55 per share in cas...
Quantexa News
03/05
CMRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Chimerix, Inc. Is Fair to Shareholders
NEW YORK--( BUSINESS WIRE )--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Chimerix, Inc. (NASDAQ: CMRX) to Jazz Pharmaceuticals plc for $8.55 per share in cash i...
Quantexa News
03/05
CMRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Chimerix, Inc. Is Fair to Shareholders
CMRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Chimerix, Inc. Is Fair to Shareholders NEW YORK--( BUSINESS WIRE )-- Halper Sadeh LLC, an investor rights law firm, is investig...
Quantexa News
03/05
CMRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Chimerix, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Chimerix, Inc. (NASDAQ: CMRX) to Jazz Pharmaceuticals plc for $8.55 per share in cash is fair to Chimerix shareholde...
Quantexa News
03/05
Chimerix CMRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Chimerix, Inc. Is Fair to Shareholders (Businesswire)
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Chimerix, Inc. (NASDAQ: CMRX) to Jazz Pharmaceuticals plc for $8.55 per share in cash is fair to Chimerix shareholde...
Quantexa News
03/05
Jazz Pharmaceuticals Expands Oncology Offering with Chimerix Deal
Jazz Pharmaceuticals Acquires Chimerix for $935 Million In a strategic move to bolster its oncology portfolio, Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has entered a definitive agreement to acquire Ch...
Quantexa News
03/05
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
Chimerix, Inc.; Jazz Pharmaceuticals plc -Dordaviprone addresses a significant unmet patient need for patients with rare, high-grade brain tumors- -Transaction to add near-term commercial opportunit...
Yahoo Finance News
03/05
Wedbush Downgrades Chimerix to Neutral From Outperform, Adjusts Price Target to $8.55 From $7
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now PREMIUM Wedbush Downgrades Chimerix to Neutral From Outperform, Adjusts Price Target to $8.55 From $7 MT Newswires W...
Quantexa News
03/05
CHIMERIX, INC. Wedbush Downgrades Chimerix to Neutral From Outperform, Adjusts Price Target to $8.55 From $7
Chimerix, Inc. is a biotechnology company. The Company is focused on developing medicines that address unmet medical needs. The Company's product Imipridones is a cancer therapy that provides ONC201,...
Quantexa News
03/05
Jazz Pharmaceuticals Expands Oncology Portfolio with Chimerix Deal
Jazz Pharmaceuticals Announces Major Acquisition In a strategic move to bolster its oncology portfolio, Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has announced its agreement to acquire Chimerix Inc (NA...
Quantexa News
03/05
Jazz Pharma To Buy Chimerix For $935 Million, Strengthening Rare Cancer Pipeline
On Tuesday, Jazz Pharmaceuticals plc JAZZ agreed to acquire Chimerix Inc CMRX for $8.55 per share in cash, representing a total consideration of approximately $935 million. Both companies have approv...
Quantexa News
03/05
Jazz Pharma To Buy Chimerix For $935 Million, Strengthening Rare Cancer Pipeline
On Tuesday, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) agreed to acquire Chimerix Inc (NASDAQ:CMRX) for $8.55 per share in cash, representing a total consideration of approximately $935 million. Both com...
Yahoo Finance News
03/05
Chimerix a Prime Acquisition Candidate for Jazz Pharmaceuticals Due to Dordaviprone, Wedbush Says
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now PREMIUM Chimerix a Prime Acquisition Candidate for Jazz Pharmaceuticals Due to Dordaviprone, Wedbush Says MT Newswir...
Quantexa News
03/05
CHIMERIX, INC. Jazz Pharmaceuticals plc entered into a definitive agreement to acquire Chimerix, Inc. for approximately $930 million.
Jazz Pharmaceuticals plc entered into a definitive agreement to acquire Chimerix, Inc. for approximately $930 million. March 04, 2025 Share Jazz Pharmaceuticals plc (NasdaqGS:JAZZ) entered into a de...
Quantexa News
03/05
Investigation Initiated for CMRX and GLYC Shareholders Rights
Investigation into Chimerix and GlycoMimetics Shareholder Rights Halper Sadeh LLC is actively investigating two notable companies: Chimerix, Inc. and GlycoMimetics, Inc. This investigation focuses on...
Yahoo Finance News
03/05
Jefferies Downgrades Chimerix to Hold From Buy, Price Target is $8.50
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now PREMIUM Jefferies Downgrades Chimerix to Hold From Buy, Price Target is $8.50 MT Newswires Wed, Mar 5, 2025, 12:30 P...
Quantexa News
03/05
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Chimerix, Inc. (Nasdaq - CMRX), Siyata Mobile Inc. (Nasdaq - SYTA), Bridge Investment Group Holdings Inc. (NYSE
March 5, 2025 12:28 PM EST BALA CYNWYD, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigat...
Quantexa News
03/05
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Chimerix, Inc. (Nasdaq - CMRX), Siyata Mobile Inc. (Nasdaq - SYTA), Bridge Investment Group Holdings Inc. (NYSE - BRDG), Intevac, Inc. (Nasdaq - IVAC)
March 05, 2025 at 12:27 PM EST BALA CYNWYD, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the invest...
Quantexa News
03/05
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Chimerix, Inc. (Nasdaq - CMRX), Siyata Mobile Inc. (Nasdaq - SYTA), Bridge Investment Group Holdings Inc. (NYSE
BALA CYNWYD, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (...
Quantexa News
03/05
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Chimerix, Inc. (Nasdaq - CMRX), Siyata Mobile Inc. (Nasdaq - SYTA), Bridge Investment Group Holdings Inc. (NYSE - BRDG), Intevac, Inc. (Nasdaq - IVAC)
BALA CYNWYD, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (...
Quantexa News
03/05
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Chimerix, Inc. (Nasdaq - CMRX), Siyata Mobile Inc. (Nasdaq - SYTA), Bridge Investment Group Holdings Inc. (NYSE - BRDG), Intevac, Inc. (Nasdaq - IVAC)
Updated BALA CYNWYD, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason...
Quantexa News
03/05
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Chimerix, Inc. (Nasdaq - CMRX), Siyata Mobile Inc. (Nasdaq - SYTA), Bridge Investment Group Holdings Inc. (NYSE - BRDG), Intevac, Inc. (Nasdaq - IVAC)
Decatur, IN Today Showers early becoming a steady rain for the afternoon. Windy. Thunder possible. High 51F. Winds SW at 20 to 30 mph. Chance of rain 90%.. Tonight Periods of rain and snow this e...
Quantexa News
03/05
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Chimerix, Inc. (Nasdaq - CMRX), Siyata Mobile Inc. (Nasdaq - SYTA), Bridge Investment Group Holdings Inc. (NYSE - BRDG), Intevac, Inc. (Nasdaq - IVAC)
BALA CYNWYD, Pa., March 05, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (...
Yahoo Finance News
03/05
Jazz Pharmaceuticals bids for Chimerix in $935m deal
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Jazz Pharmaceuticals bids for Chimerix in $935m deal Dordaviprone is under review with the FDA for a rare and aggres...
Quantexa News
03/05
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Chimerix, Inc. Buyout
March 5, 2025 1:19 PM EST Wilmington, Delaware--(Newsfile Corp. - March 5, 2025) - Rigrodsky Law, P.A. is investigating Chimerix, Inc. ("Chimerix") (NASDAQ: CMRX ) regarding possible breaches of fidu...
Quantexa News
03/05
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Chimerix, Inc. Buyout
Wilmington, Delaware--(Newsfile Corp. - March 5, 2025) - Rigrodsky Law, P.A. is investigating Chimerix, Inc. ("Chimerix") (NASDAQ: CMRX) regarding possible breaches of fiduciary duties and other viola...
Quantexa News
03/05
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Chimerix, Inc. Buyout
Wilmington, Delaware--(Newsfile Corp. - March 5, 2025) - Rigrodsky Law, P.A. is investigating Chimerix, Inc. ("Chimerix") (NASDAQ: CMRX) regarding possible breaches of fiduciary duties and other viola...
Quantexa News
03/05
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Chimerix, Inc. Buyout
Wilmington, Delaware--(Newsfile Corp. - March 5, 2025) - Rigrodsky Law, P.A. is investigating Chimerix, Inc. ("Chimerix") (NASDAQ: CMRX) regarding possible breaches of fiduciary duties and other viola...
Quantexa News
03/05
Investigation of Potential Violations at CMRX, IVAC, and BRDG
Halper Sadeh LLC's Investigation Overview Halper Sadeh LLC, a law firm focused on investor rights, has initiated investigations into several companies over potential breaches of fiduciary duties and...
Quantexa News
03/05
Form SC14D9C - Written communication relating to third party tender offer
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 Chime...
Quantexa News
03/05
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Chimerix, Inc. - CMRX
NEW YORK March 5, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities...
Quantexa News
03/05
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Chimerix, Inc. - CMRX
NEW YORK March 5, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities...
Quantexa News
03/05
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Chimerix, Inc. - CMRX
Click here for more https://monteverdelaw.com/case/chimerix-inc-cmrx/ It is free and there is no cost or obligation to you. NOT ALL LAW FIRMS ARE THE SAME. Before you hire a law firm, you should talk...
Quantexa News
03/05
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Chimerix, Inc. - CMRX PR Newswire Today at 11:00pm GMT+1
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Chimerix, Inc. - CMRX PR Newswire NEW YORK, March 5, 2025 NEW YORK, March 5, 2025 /PRNewswire/ -- Monteverde & Associates PC (th...
Quantexa News
03/05
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Chimerix, Inc. - CMRX
PR Newswire Today at 11:00pm GMT+1 $HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Chimerix, Inc. - CMRX PR Newswire NEW YORK, March 5, 2025 NEW YORK March 5, 2025 /PRNe...
Quantexa News
03/05
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Chimerix, Inc. - CMRX
NEW YORK, March 5, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securitie...
Quantexa News
03/05
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Chimerix, Inc. - CMRX
By Monteverde & Associates PC NEW YORK March 5, 2025 /PRNewswire/ -- (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securi...
Quantexa News
03/05
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Chimerix, Inc. - CMRX
We and our partnersstore and/or access information on a device, such as cookies and process personal data, such as unique identifiers and standard information sent by a device for personalised adverti...
Quantexa News
03/05
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Chimerix, Inc. - CMRX
News provided by Monteverde & Associates PC Mar 05, 2025, 5:00 PM ET NEW YORK March 5, 2025 /PRNewswire/ -- (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is...
Quantexa News
03/05
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Chimerix, Inc. - CMRX
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Chimerix, Inc. - CMRX NEW YORK March 5, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has reco...
Quantexa News
03/05
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Chimerix, Inc. - CMRX
PR Newswire NEW YORK, March 5, 2025 NEW YORK March 5, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recogni...
Quantexa News
03/05
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Chimerix, Inc. - CMRX
News provided by Monteverde & Associates PC Mar 05, 2025, 5:00 PM ET NEW YORK March 5, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dolla...
Quantexa News
03/05
Chimerix $HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Chimerix, Inc. - CMRX (PR Newswire)
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Chimerix, Inc. - CMRX PR Newswire NEW YORK, March 5, 2025 NEW YORK , March 5, 2025 /PRNewswire/ -- (the "M&A Class Action Fir...
Quantexa News
03/05
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates The Merger Of Chimerix, Inc. - CMRX
MENAFN - PR Newswire) NEW YORK, March 5, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50...
Quantexa News
03/05
Jazz To Buy Chimerix For $935 Mln To Boost Oncology Portfolio, CMRX Up In Pre-Market
(RTTNews) - Jazz Pharmaceuticals Plc. (JAZZ), Wednesday announced a deal to acquire Chimerix Inc. (CMRX) for $8.55 per share in cash, or a total consideration of around $935 million. Under the terms,...
Quantexa News
03/06
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Chimerix, Inc. - CMRX
NEW YORK March 5, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities...
Quantexa News
03/06
Jazz To Buy Chimerix For $935 Mln To Boost Oncology Portfolio, CMRX Up In Pre-Market
(RTTNews) - Jazz Pharmaceuticals Plc. (JAZZ), Wednesday announced a deal to acquire Chimerix Inc. (CMRX) for $8.55 per share in cash, or a total consideration of around $935 million. Under the terms,...
Yahoo Finance News
03/06
Update: Truist Raises PT on Jazz Pharmaceuticals to $230 From $220 on Heels of Announced Purchase of Chimerix, Keeps Buy Rating
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now PREMIUM Update: Truist Raises PT on Jazz Pharmaceuticals to $230 From $220 on Heels of Announced Purchase of Chimeri...
Yahoo Finance News
03/07
The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals Zacks Equity Resea...
Quantexa News
03/07
CMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. is Fair to Shareholders
March 07, 2025 at 07:48 AM EST NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Chimerix, Inc. (NASDAQ: CMRX) to Jazz P...
Quantexa News
03/07
CMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. is Fair to Shareholders
NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Chimerix, Inc. (NASDAQ: CMRX) to Jazz Pharmaceuticals plc for $8.55 per...
Quantexa News
03/07
CMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. is Fair to Shareholders
GlobeNewswire | Halper Sadeh LLC Today at 1:48pm GMT+1 NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Chimerix, Inc....
Quantexa News
03/07
Chimerix, Inc. Stock Sale Under Investigation: What You Need to Know
Chimerix, Inc. Under Investigation for Stock Sale Fairness Investor rights law firm Halper Sadeh LLC is currently investigating whether the sale of Chimerix, Inc. (NASDAQ: CMRX) to Jazz Pharmaceutica...
Quantexa News
03/07
CMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. is Fair to Shareholders
NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Chimerix, Inc. (NASDAQ: CMRX) to Jazz Pharmaceuticals plc for $8.55 per...
Quantexa News
03/07
CMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. is Fair to Shareholders GlobeNewswire | Halper Sadeh LLC Today at 1:48pm GMT+1
NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Chimerix, Inc. (NASDAQ: CMRX) to Jazz Pharmaceuticals plc for $8.55 per...
Quantexa News
03/07
CMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. is Fair to Shareholders
NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Chimerix, Inc. (NASDAQ: CMRX) to Jazz Pharmaceuticals plc for $8.55 per...
Quantexa News
03/07
CMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. is Fair to Shareholders
GlobeNewswire | Halper Sadeh LLC Today at 1:48pm GMT+1 NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Chimerix, Inc....
Quantexa News
03/07
CMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. is Fair to Shareholders
NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Chimerix, Inc. (NASDAQ: CMRX) to Jazz Pharmaceuticals plc for $8.55 per...
Quantexa News
03/07
CMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. is Fair...
NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Chimerix, Inc. (NASDAQ: CMRX) to Jazz Pharmaceuticals plc for $8.55 per...
Quantexa News
03/07
CMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. is Fair to Shareholders
Decatur, IN Today Cloudy early, then off and on rain showers for the afternoon. High 41F. Winds S at 5 to 10 mph. Chance of rain 50%.. Tonight Showers early, then cloudy overnight. Low 29F. Winds...
Quantexa News
03/07
Chimerix (NASDAQ:CMRX) Sees Strong Trading Volume – Should You Buy?
Shares of Chimerix, Inc. (NASDAQ:CMRX – Get Free Report) saw unusually-high trading volume on Friday . Approximately 3,735,715 shares traded hands during mid-day trading, an increase of 86% from the p...
Quantexa News
03/07
Chimerix (NASDAQ:CMRX) Sees Large Volume Increase – Should You Buy?
Chimerix, Inc. (NASDAQ:CMRX – Get Free Report) shares saw strong trading volume on Friday . 3,735,715 shares traded hands during trading, an increase of 86% from the previous session’s volume of 2,013...
Yahoo Finance News
03/07
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Chimerix, Inc. Fri, Mar 7, 2025, 1:01 PM 1 m...
Quantexa News
03/08
Chimerix (NASDAQ:CMRX) Sets New 12-Month High – What's Next?
Chimerix, Inc. ( NASDAQ:CMRX – Get Free Report ) shares reached a new 52-week high on Thursday . The company traded as high as $8.47 and last traded at $8.46, with a volume of 118514429 shares trading...
Quantexa News
03/08
Chimerix (NASDAQ:CMRX) Sees Strong Trading Volume - Should You Buy?
Shares of Chimerix, Inc. (NASDAQ:CMRX - Get Free Report) saw unusually-high trading volume on Friday . Approximately 3,735,715 shares traded hands during mid-day trading, an increase of 86% from the p...
Polygon News
03/08
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VOXX, CMRX, WBA, ML on Behalf of Shareholders
Halper Sadeh LLC is investigating potential violations of federal securities laws and/or breaches of fiduciary duties to shareholders related to the proposed sales of VOXX International Corporation, C...
Quantexa News
03/09
Chimerix (NASDAQ:CMRX) Sees Unusually-High Trading Volume – Here's Why
Chimerix, Inc. ( NASDAQ:CMRX – Get Free Report ) shares saw strong trading volume on Friday . 3,735,715 shares traded hands during mid-day trading, an increase of 86% from the previous session's volum...
Quantexa News
03/10
CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRX
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Chimerix, Inc. (NasdaqGM: CMRX) to Jazz Pharma...
Quantexa News
03/10
CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRX
March 10, 2025 at 22:33 PM EDT Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of (“KSF”) are investigating the proposed sale of (NasdaqGM: CMRX) to Jazz Pharmaceutic...
Quantexa News
03/10
CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRX
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Chimerix, Inc. (NasdaqGM: CMRX) to Jazz Pharma...
Quantexa News
03/10
CHIMERIX, INC. CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRX
March 10, 2025 at 10:34 pm EDT Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Chimerix, Inc....
Quantexa News
03/10
CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRX
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Mar 10, 2025-- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the propos...
Quantexa News
03/10
CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRX
NEW YORK & NEW ORLEANS--( BUSINESS WIRE )--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Chi...
Quantexa News
03/10
CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRX
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Chimerix, Inc. (NasdaqGM: CMRX) to Jazz Pharma...
Quantexa News
03/10
CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRX
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Chimerix, Inc. (NasdaqGM: CMRX) to Jazz Pharma...
Quantexa News
03/11
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 2seventy bio, Inc. (Nasdaq - TSVT), Bridge Investment Group Holdings Inc. (NYSE - BRDG), Chimerix, Inc. (Nasdaq - CMRX), 180 Degree Capital Corp. (Nasdaq – TURN)
BALA CYNWYD, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (...
Quantexa News
03/11
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 2seventy bio, Inc. (Nasdaq - TSVT), Bridge Investment Group Holdings Inc. (NYSE - BRDG), Chimerix, Inc. (Nasdaq - CMRX), 180 Degree Capital Corp. (Nasdaq – TURN)
GlobeNewswire | Brodsky & Smith LLC Today at 8:35pm GMT+1 BALA CYNWYD, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares an...
Quantexa News
03/11
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 2seventy bio, Inc. (Nasdaq - TSVT), Bridge Investment Group Holdings Inc. (NYSE - BRDG), Chimerix, Inc. (Nasdaq - CMRX), 180 Degree Capital Corp. (Nasdaq – TURN)
GlobeNewswire | Brodsky & Smith LLC BALA CYNWYD, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the i...
Quantexa News
03/11
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 2seventy bio, Inc. (Nasdaq - TSVT), Bridge Investment Group Holdings Inc. (NYSE - BRDG), Chimerix, Inc. (Nasdaq
Ad blocking detected Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot s...
Quantexa News
03/11
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 2seventy bio, Inc. (Nasdaq - TSVT), Bridge Investment Group Holdings Inc. (NYSE - BRDG), Chimerix, Inc. (Nasdaq - CMRX), 180 Degree Capital Corp. (Nasdaq – TURN)
BALA CYNWYD, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (...
Quantexa News
03/11
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 2seventy bio, Inc. (Nasdaq - TSVT), Bridge Investment Group Holdings Inc. (NYSE - BRDG), Chimerix, Inc. (Nasdaq - CMRX), 180 Degree Capital Corp. (Nasdaq – TURN)
BALA CYNWYD, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (...
Quantexa News
03/11
Chimerix CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRX (Businesswire)
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Chimerix, Inc. (NasdaqGM: CMRX) to Jazz Pharma...
Quantexa News
03/12
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors Of The Following Investigations: 2Seventy Bio, Inc. (Nasdaq - TSVT), Bridge Investment Group Holdings Inc. (NYSE - BRDG), Chimerix, Inc. (Nasdaq - CMRX), 180 Degree Capital Corp. (Nasdaq – TURN)
- GlobeNewsWire - Nasdaq) BALA CYNWYD, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigatio...
Quantexa News
03/12
Bender Robert & Associates Acquires New Holdings in Chimerix, Inc. (NASDAQ:CMRX)
Bender Robert & Associates acquired a new stake in Chimerix, Inc. ( NASDAQ:CMRX – Free Report ) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commiss...
Polygon News
03/12
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDFN, BLBX, CMRX, WBA on Behalf of Shareholders
Halper Sadeh LLC is investigating potential violations of federal securities laws and/or breaches of fiduciary duties to shareholders related to the proposed sales of Redfin, Blackboxstocks, Chimerix,...
Quantexa News
03/12
Chimerix (NASDAQ:CMRX) Sets New 12-Month High – Here's What Happened
Chimerix, Inc. ( NASDAQ:CMRX – Get Free Report ) shares reached a new 52-week high during trading on Wednesday . The stock traded as high as $8.47 and last traded at $8.47, with a volume of 1029993 sh...
Quantexa News
03/14
Chimerix (NASDAQ:CMRX) Sets New 12-Month High - Here's What Happened
Chimerix, Inc. (NASDAQ:CMRX - Get Free Report) shares reached a new 52-week high during trading on Wednesday . The stock traded as high as $8.47 and last traded at $8.47, with a volume of 1029993 shar...
